YAMATO研究:替奈普酶与依达拉奉联合治疗
结果显示两组tPA后1.5小时早期再通率均为53%(P=1.000),症状性颅内出血、3个月良好预后均无显著差异。结论认为依达拉奉给药时机不影响tPA治疗后早期再通、出血或预后。
要点
- 早期与晚期依达拉奉组tPA后1.5小时早期再通率均为53%。
- 症状性颅内出血率早期组5%、晚期组2%,无显著差异。
- 3个月良好预后(mRS 0-2)两组相似(53% vs 57%)。
核心结论
- 依达拉奉给药时机不影响tPA治疗后早期再通率、症状性颅内出血或良好预后。
研究设计与样本
- 研究者发起的多中心(日本17家医院)前瞻性随机开放标签研究。
主要发现
- tPA后1.5小时早期再通率早期组53%、晚期组53%(P=1.000)。
- 显著再通≥50%的比例两组无差异(28% vs 34%;P=0.393)。
- 症状性颅内出血早期组4例(5%)、晚期组2例(2%)(P=0.443)。
- 3个月良好预后(mRS 0-2)两组相似(53% vs 57%;P=0.738)。
临床怎么用
- 对于大脑中动脉M1或M2段闭塞且发病4.5小时内的卒中患者,依达拉奉在tPA前或后给药对早期再通和预后无显著影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We investigated whether administration of edaravone, a free radical scavenger, before or during tissue-type plasminogen activator (tPA) can enhance early recanalization in a major arterial occlusion. METHODS: The YAMATO study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy) is an investigator-initiated, multicenter (17 hospitals in Japan), prospective, randomized, and open-label study. Patients with stroke secondary to occlusion of the M1 or M2 portion of the middle cerebral artery and within 4.5 hours of the onset were studied. The subjects were randomly allocated to the early group (intravenous edaravone [30 mg] was started before or during tPA) and the late group (edaravone was started after tPA and the assessment of early recanalization). RESULTS: One-hundred sixty-five patients (96 men; median age [interquartile range], of 78 [69-85] years) were randomized 1:1 to either the early group (82 patients) or the late group (83 patients). Primary outcome, defined as an early recanalization 1.5 hour after tPA, was observed in 53% of the early group and in 53% of the late group (P=1.000). About secondary outcomes, the rate of significant recanalization of ≥50% was not different between the 2 groups (28% versus 34%; P=0.393). The symptomatic intracerebral hemorrhage has occurred in 4 patients (5%) in the early group and in 2 patients (2%) in the late group (P=0.443). The favorable outcome (modified Rankin Scale score of 0-2) at 3 months was also similar between the groups (53% versus 57%; P=0.738). CONCLUSIONS: The timing of edaravone infusion does not affect the rate of early recanalization, symptomatic intracerebral hemorrhage, or favorable outcome after tPA therapy. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr/index-j.htm. Unique identifier: UMIN000006330.
引用
- Aoki J, Kimura K, Morita N, et al. YAMATO Study (Tissue-Type Plasminogen Activator and Edaravone Combination Therapy). Stroke. 2017. PMID: 28119434. doi:10.1161/STROKEAHA.116.015042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。